Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.

MLA

Kantarjian, H. M., et al. “Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 18, no. 20, Oct. 2000, pp. 3513–21. EBSCOhost, https://doi.org/10.1200/JCO.2000.18.20.3513.

APA

Kantarjian, H. M., Talpaz, M., Smith, T. L., Cortes, J., Giles, F. J., Rios, M. B., Mallard, S., Gajewski, J., Murgo, A., Cheson, B., & O’Brien, S. (2000). Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 18(20), 3513–3521. https://doi.org/10.1200/JCO.2000.18.20.3513

Chicago

Kantarjian, H M, M Talpaz, T L Smith, J Cortes, F J Giles, M B Rios, S Mallard, et al. 2000. “Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 18 (20): 3513–21. doi:10.1200/JCO.2000.18.20.3513.